BMS Moves Closer To Subcutaneous Opdivo With Phase III Trial Success

 
• By Joseph Haas

A Phase III trial testing subcutaneous nivolumab versus the intravenous product hits pharmacokinetic and efficacy endpoints. BMS, Roche and Merck & Co. all are seeking subcutaneous versions of their anti-PD-1/L1 blockbusters.

Chemical process
Bristol makes progress in formulating a subcutaneous version of Opdivo • Source: Shutterstock

More from Immuno-oncology

More from Anticancer